New England Journal of Medicine publishes long-term results of Gleevec for patients with chronic myeloid leukemia

March 9, 2017, Oregon Health & Science University

In 2001 the U.S. Food and Drug Administration granted priority review for imatinib mesylate, sold under the name Gleevec, as an oral therapy for patients with chronic myeloid leukemia, or CML.

Today the New England Journal of Medicine published results from a nearly 11-year follow-up study, that showed an estimated overall survival rate of 83.3 percent. According to the National Cancer Institute, prior to Gleevec's 2001 FDA approval, fewer than 1 in 3 CML patients survived five years past diagnosis.

Brian Druker, M.D., who led the original clinical development of Gleevec, co-authored the study. The worldwide study enrolled 1,106 participants at 177 cancer centers in more than 16 countries.

"The long-term success of this treatment confirms the remarkable success we've seen since the very first Gleevec trials," said Druker, director of the OHSU Knight Cancer Institute, a Howard Hughes Medical Institute Investigator and JELD-WEN Chair of Leukemia Research in the OHSU School of Medicine. "This study reinforces the notion that we can create effective and non-toxic therapies."

The discovery of Gleevec ushered in the era of personalized cancer medicine, proving it was possible to shut down cells that enable cancer to grow without harming healthy ones.

In an accompanying editorial, "Imatinib Changed Everything," Dan Longo, M.D., professor of medicine, Harvard Medical School; and deputy editor, the New England Journal of Medicine, wrote: "The development of imatinib fundamentally altered the field of oncology. Priorities shifted from agents that were active on dividing cells to understanding the biology of individual types of cancer."

In addition to treating patients with CML, Gleevec has proved effective against multiple forms of cancer, including pediatric CML and , or GIST. A recent study published in JAMA Oncology found that nearly 1 in 4 GIST patients treated with Gleevec will survive 10 years.

"Until Gleevec arrived on the scene 15 years ago, patients with advanced GISTs faced a life expectancy of 18 months," said Michael Heinrich, M.D., a professor of medicine (hematology and medical oncology) and cell and developmental biology in the OHSU School of Medicine; researcher with Portland Veterans Affairs Health Care System. "Now we've learned that some might live a decade or longer."

Druker says one advantage to treating CML patients with Gleevec is that most patients are diagnosed in a chronic stage of their illness: "Our results demonstrating Gleevec's high efficacy in CML tell us to realize the full promise of precision medicine, we need to diagnose and treat patients earlier in the disease course."

Explore further: Study shows strong long-term survival rates for patients with GIST

More information: Long-Term Outcomes of Imatinib Treatment for Chronic Myeloid Leukemia, www.nejm.org/doi/full/10.1056/NEJMoa1609324

Related Stories

Study shows strong long-term survival rates for patients with GIST

February 20, 2017
Nine years ago, SWOG researchers confirmed a new standard of care for patients with incurable gastrointestinal stromal tumors (GIST), who could survive by being treated with imatinib mesylate, the breakthrough drug marketed ...

Risk & reward: Stopping a cancer drug to see if you're cured

March 2, 2017
Imagine you had a life-threatening cancer that a wonder drug had kept in remission for years. Would you risk quitting?

Gleevec's latest approval is for pediatric cancer

January 25, 2013
(HealthDay)—The anti-cancer drug Gleevec (imatinib) has received new U.S. Food and Drug Administration approval to treat the most common type of pediatric cancer, affecting some 2,900 children each year, the agency said ...

FDA OKs first generic for Gleevec leukemia pill

December 4, 2015
U.S. regulators have approved the first generic version of one of the first very effective—and expensive—cancer drugs, Gleevec, which costs about $10,000 a month.

Recommended for you

Researchers discover novel mechanism linking changes in mitochondria to cancer cell death

February 20, 2018
To stop the spread of cancer, cancer cells must die. Unfortunately, many types of cancer cells seem to use innate mechanisms that block cancer cell death, therefore allowing the cancer to metastasize. While seeking to further ...

Stem cell vaccine immunizes lab mice against multiple cancers

February 15, 2018
Stanford University researchers report that injecting mice with inactivated induced pluripotent stem cells (iPSCs) launched a strong immune response against breast, lung, and skin cancers. The vaccine also prevented relapses ...

Induced pluripotent stem cells could serve as cancer vaccine, researchers say

February 15, 2018
Induced pluripotent stem cells, or iPS cells, are a keystone of regenerative medicine. Outside the body, they can be coaxed to become many different types of cells and tissues that can help repair damage due to trauma or ...

Team paves the way to the use of immunotherapy to treat aggressive colon tumors

February 15, 2018
In a short space of time, immunotherapy against cancer cells has become a powerful approach to treat cancers such as melanoma and lung cancer. However, to date, most colon tumours appeared to be unresponsive to this kind ...

Can our genes help predict how women respond to ovarian cancer treatment?

February 15, 2018
Research has identified gene variants that play a significant role in how women with ovarian cancer process chemotherapy.

First comparison of common breast cancer tests finds varied accuracy of predictions

February 15, 2018
Commercially-available prognostic breast cancer tests show significant variation in their abilities to predict disease recurrence, according to a study led by Queen Mary University of London of nearly 800 postmenopausal women.

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.